bioAffinity Technologies, Inc. 8-K

What Happened

• bioAffinity Technologies, Inc. (BIAF) filed an 8-K on May 12, 2026, attaching a press release that announced unit sales for its CyPath® Lung diagnostic test reached a record high in a single month. Based on preliminary, unaudited data, unit sales in April 2026 increased nearly 300% compared with April 2025. The press release is included as Exhibit 99.1 to the filing.

Key Details

• Filing date: May 12, 2026 (Form 8-K, Item 8.01 Other Events).
• Product: CyPath® Lung diagnostic test.
• Growth: Unit sales increased nearly 300% in April 2026 vs April 2025 (preliminary, unaudited).
• Disclosure: Announcement made via press release (Exhibit 99.1); no audited revenue, earnings, or quarterly financial figures were provided in this 8-K.

Why It Matters

• A sharp, reported rise in unit sales indicates growing commercial traction for the CyPath Lung test, which could translate into higher future revenue if trends continue and are reflected in the company’s formal financial reports.
• This filing notifies investors of operational progress but is not a replacement for audited quarterly or annual results; investors should watch upcoming earnings/quarterly reports for confirmed revenue and earnings impact.